ES2206729T3 - Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosina quinasa. - Google Patents
Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosina quinasa.Info
- Publication number
- ES2206729T3 ES2206729T3 ES97930518T ES97930518T ES2206729T3 ES 2206729 T3 ES2206729 T3 ES 2206729T3 ES 97930518 T ES97930518 T ES 97930518T ES 97930518 T ES97930518 T ES 97930518T ES 2206729 T3 ES2206729 T3 ES 2206729T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- group
- pyrimidin
- benzyl
- indazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title claims abstract description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 title claims abstract description 5
- 239000003112 inhibitor Substances 0.000 title abstract description 9
- 102000004169 proteins and genes Human genes 0.000 title abstract description 5
- 108090000623 proteins and genes Proteins 0.000 title abstract description 5
- 150000002390 heteroarenes Chemical class 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 216
- 238000000034 method Methods 0.000 claims abstract description 79
- 238000011282 treatment Methods 0.000 claims abstract description 26
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 8
- 201000011510 cancer Diseases 0.000 claims abstract description 8
- -1 hydroxy, hydroxy Chemical group 0.000 claims description 207
- 125000000217 alkyl group Chemical group 0.000 claims description 100
- 229910052739 hydrogen Inorganic materials 0.000 claims description 60
- 239000001257 hydrogen Substances 0.000 claims description 55
- 238000006243 chemical reaction Methods 0.000 claims description 40
- 229910052757 nitrogen Inorganic materials 0.000 claims description 38
- 239000000376 reactant Substances 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 37
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 36
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 33
- 239000012453 solvate Substances 0.000 claims description 31
- 125000003282 alkyl amino group Chemical group 0.000 claims description 28
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 28
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 25
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 21
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 20
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 20
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 19
- 125000005843 halogen group Chemical group 0.000 claims description 19
- 150000002431 hydrogen Chemical class 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- QNDFCSITSCMNGP-UHFFFAOYSA-N n-(1-benzylindazol-5-yl)-6-chloropyrido[3,4-d]pyrimidin-4-amine Chemical compound N1=CN=C2C=NC(Cl)=CC2=C1NC(C=C1C=N2)=CC=C1N2CC1=CC=CC=C1 QNDFCSITSCMNGP-UHFFFAOYSA-N 0.000 claims description 18
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 16
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 15
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 14
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 125000004175 fluorobenzyl group Chemical group 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 125000001041 indolyl group Chemical group 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 11
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 10
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 10
- 125000001589 carboacyl group Chemical group 0.000 claims description 10
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 150000003852 triazoles Chemical class 0.000 claims description 9
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 8
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- YUSMWODGNWPEBC-UHFFFAOYSA-N n-morpholin-4-ylacetamide Chemical compound CC(=O)NN1CCOCC1 YUSMWODGNWPEBC-UHFFFAOYSA-N 0.000 claims description 8
- PDUSWJORWQPNRP-UHFFFAOYSA-N n-propan-2-ylacetamide Chemical compound CC(C)NC(C)=O PDUSWJORWQPNRP-UHFFFAOYSA-N 0.000 claims description 8
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 8
- DYYZXRCFCVDSKD-UHFFFAOYSA-N N6,N6-dimethyl-N4-[1-(phenylmethyl)-5-indazolyl]pyrido[3,4-d]pyrimidine-4,6-diamine Chemical compound N1=CN=C2C=NC(N(C)C)=CC2=C1NC(C=C1C=N2)=CC=C1N2CC1=CC=CC=C1 DYYZXRCFCVDSKD-UHFFFAOYSA-N 0.000 claims description 7
- 125000005879 dioxolanyl group Chemical group 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- MISVBCMQSJUHMH-UHFFFAOYSA-N pyrimidine-4,6-diamine Chemical compound NC1=CC(N)=NC=N1 MISVBCMQSJUHMH-UHFFFAOYSA-N 0.000 claims description 7
- JCMRKIPIHJRILY-UHFFFAOYSA-N 5-[4-[(1-benzylindazol-5-yl)amino]pyrido[3,4-d]pyrimidin-6-yl]furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1C(N=CC1=NC=N2)=CC1=C2NC1=CC=C(N(CC=2C=CC=CC=2)N=C2)C2=C1 JCMRKIPIHJRILY-UHFFFAOYSA-N 0.000 claims description 6
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 6
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 6
- 150000003536 tetrazoles Chemical class 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
- JFXFEXXASOCJBR-UHFFFAOYSA-N 4-n-(1-benzylindazol-5-yl)-6-n-ethyl-6-n-methylpyrido[3,4-d]pyrimidine-4,6-diamine Chemical compound N1=CN=C2C=NC(N(C)CC)=CC2=C1NC(C=C1C=N2)=CC=C1N2CC1=CC=CC=C1 JFXFEXXASOCJBR-UHFFFAOYSA-N 0.000 claims description 5
- BMIOWXJYLRLVHA-UHFFFAOYSA-N 4-n-(1-benzylindazol-5-yl)-6-n-methylpyrido[3,4-d]pyrimidine-4,6-diamine Chemical compound N1=CN=C2C=NC(NC)=CC2=C1NC(C=C1C=N2)=CC=C1N2CC1=CC=CC=C1 BMIOWXJYLRLVHA-UHFFFAOYSA-N 0.000 claims description 5
- RLCKHNKPUUYNQD-UHFFFAOYSA-N 5-[4-[(1-benzylindazol-5-yl)amino]pyrido[3,4-d]pyrimidin-6-yl]furan-2-carbaldehyde Chemical compound O1C(C=O)=CC=C1C(N=CC1=NC=N2)=CC1=C2NC1=CC=C(N(CC=2C=CC=CC=2)N=C2)C2=C1 RLCKHNKPUUYNQD-UHFFFAOYSA-N 0.000 claims description 5
- VLJNHYLEOZPXFW-BYPYZUCNSA-N L-prolinamide Chemical compound NC(=O)[C@@H]1CCCN1 VLJNHYLEOZPXFW-BYPYZUCNSA-N 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 5
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 5
- 150000004702 methyl esters Chemical class 0.000 claims description 5
- HKNPEKHQRROZPD-UHFFFAOYSA-N 4-n-[1-[(3-fluorophenyl)methyl]indazol-5-yl]-6-n,6-n-dimethylpyrido[3,4-d]pyrimidine-4,6-diamine Chemical compound N1=CN=C2C=NC(N(C)C)=CC2=C1NC(C=C1C=N2)=CC=C1N2CC1=CC=CC(F)=C1 HKNPEKHQRROZPD-UHFFFAOYSA-N 0.000 claims description 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 4
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 4
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- MLLMAIJXIZOSFS-UHFFFAOYSA-N n,n-dimethylpyrrolidine-2-carboxamide Chemical compound CN(C)C(=O)C1CCCN1 MLLMAIJXIZOSFS-UHFFFAOYSA-N 0.000 claims description 4
- GIZAHSJRRRUFEE-UHFFFAOYSA-N n-(1-benzylindazol-5-yl)-6-[5-(1,3-dioxolan-2-yl)furan-2-yl]pyrido[3,4-d]pyrimidin-4-amine Chemical compound N1=CC2=CC(NC=3C4=CC(=NC=C4N=CN=3)C=3OC(=CC=3)C3OCCO3)=CC=C2N1CC1=CC=CC=C1 GIZAHSJRRRUFEE-UHFFFAOYSA-N 0.000 claims description 4
- YCPVGYFQXXTANI-UHFFFAOYSA-N n-(2-benzyl-3h-benzimidazol-5-yl)-6-chloropyrido[3,4-d]pyrimidin-4-amine Chemical compound N1=CN=C2C=NC(Cl)=CC2=C1NC(C=C1N=2)=CC=C1NC=2CC1=CC=CC=C1 YCPVGYFQXXTANI-UHFFFAOYSA-N 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 229930192474 thiophene Natural products 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 229910052721 tungsten Inorganic materials 0.000 claims description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 3
- XJKWUSYIOHJDIM-UHFFFAOYSA-N 2-[[4-[(1-benzylindazol-5-yl)amino]pyrido[3,4-d]pyrimidin-6-yl]-methylamino]ethanol Chemical compound N1=CN=C2C=NC(N(CCO)C)=CC2=C1NC(C=C1C=N2)=CC=C1N2CC1=CC=CC=C1 XJKWUSYIOHJDIM-UHFFFAOYSA-N 0.000 claims description 3
- XKGUJMPYDBMSDA-UHFFFAOYSA-N 4-n-(1-benzyl-3-methylindazol-5-yl)-6-n,6-n-dimethylpyrido[3,4-d]pyrimidine-4,6-diamine Chemical compound N1=CN=C2C=NC(N(C)C)=CC2=C1NC(C=C1C(C)=N2)=CC=C1N2CC1=CC=CC=C1 XKGUJMPYDBMSDA-UHFFFAOYSA-N 0.000 claims description 3
- YZZIGXZRNAEFCP-UHFFFAOYSA-N 4-n-(1-benzylindol-5-yl)-6-n,6-n-dimethylpyrido[3,4-d]pyrimidine-4,6-diamine Chemical compound N1=CN=C2C=NC(N(C)C)=CC2=C1NC(C=C1C=C2)=CC=C1N2CC1=CC=CC=C1 YZZIGXZRNAEFCP-UHFFFAOYSA-N 0.000 claims description 3
- BIQOFKWYWPJGNB-UHFFFAOYSA-N 4-n-[1-(benzenesulfonyl)indol-5-yl]-6-n,6-n-dimethylpyrido[3,4-d]pyrimidine-4,6-diamine Chemical compound N1=CN=C2C=NC(N(C)C)=CC2=C1NC(C=C1C=C2)=CC=C1N2S(=O)(=O)C1=CC=CC=C1 BIQOFKWYWPJGNB-UHFFFAOYSA-N 0.000 claims description 3
- HBOLGDVBJIQIQE-UHFFFAOYSA-N 4-n-[1-[(2-fluorophenyl)methyl]indazol-5-yl]-6-n,6-n-dimethylpyrido[3,4-d]pyrimidine-4,6-diamine Chemical compound N1=CN=C2C=NC(N(C)C)=CC2=C1NC(C=C1C=N2)=CC=C1N2CC1=CC=CC=C1F HBOLGDVBJIQIQE-UHFFFAOYSA-N 0.000 claims description 3
- MQNRGKYCHYKEMO-UHFFFAOYSA-N 4-n-[1-[(4-fluorophenyl)methyl]indazol-5-yl]-6-n,6-n-dimethylpyrido[3,4-d]pyrimidine-4,6-diamine Chemical compound N1=CN=C2C=NC(N(C)C)=CC2=C1NC(C=C1C=N2)=CC=C1N2CC1=CC=C(F)C=C1 MQNRGKYCHYKEMO-UHFFFAOYSA-N 0.000 claims description 3
- OCCGRAZNBVMQAO-UHFFFAOYSA-N 4-n-[3-(benzenesulfonyl)-1h-indol-5-yl]-6-n,6-n-dimethylpyrido[3,4-d]pyrimidine-4,6-diamine Chemical compound N1=CN=C2C=NC(N(C)C)=CC2=C1NC(C=C12)=CC=C1NC=C2S(=O)(=O)C1=CC=CC=C1 OCCGRAZNBVMQAO-UHFFFAOYSA-N 0.000 claims description 3
- VKPHMHJHCQWKKV-UHFFFAOYSA-N 6-n,6-n-dimethyl-4-n-[1-(pyridin-2-ylmethyl)indazol-5-yl]pyrido[3,4-d]pyrimidine-4,6-diamine Chemical compound N1=CN=C2C=NC(N(C)C)=CC2=C1NC(C=C1C=N2)=CC=C1N2CC1=CC=CC=N1 VKPHMHJHCQWKKV-UHFFFAOYSA-N 0.000 claims description 3
- USTNKMJFNDVPLS-UHFFFAOYSA-N 6-n,6-n-dimethyl-4-n-[1-(pyridin-3-ylmethyl)indazol-5-yl]pyrido[3,4-d]pyrimidine-4,6-diamine Chemical compound N1=CN=C2C=NC(N(C)C)=CC2=C1NC(C=C1C=N2)=CC=C1N2CC1=CC=CN=C1 USTNKMJFNDVPLS-UHFFFAOYSA-N 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 3
- UZXVIZOKQMXWKF-UHFFFAOYSA-N n-(1-benzylindazol-5-yl)-6-(3-methylimidazol-4-yl)pyrido[3,4-d]pyrimidin-4-amine Chemical compound CN1C=NC=C1C(N=CC1=NC=N2)=CC1=C2NC1=CC=C(N(CC=2C=CC=CC=2)N=C2)C2=C1 UZXVIZOKQMXWKF-UHFFFAOYSA-N 0.000 claims description 3
- NEHINJYPPQYUQH-UHFFFAOYSA-N n-(1-benzylindazol-5-yl)-6-imidazol-1-ylpyrido[3,4-d]pyrimidin-4-amine Chemical compound N1=CC2=CC(NC=3C4=CC(=NC=C4N=CN=3)N3C=NC=C3)=CC=C2N1CC1=CC=CC=C1 NEHINJYPPQYUQH-UHFFFAOYSA-N 0.000 claims description 3
- OEYOUMHPXUXUIQ-UHFFFAOYSA-N n-(1-benzylindazol-5-yl)-6-piperidin-1-ylpyrido[3,4-d]pyrimidin-4-amine Chemical compound N1=CC2=CC(NC=3C4=CC(=NC=C4N=CN=3)N3CCCCC3)=CC=C2N1CC1=CC=CC=C1 OEYOUMHPXUXUIQ-UHFFFAOYSA-N 0.000 claims description 3
- WVIYDZAMWSNDDO-UHFFFAOYSA-N n-(1-benzylindazol-5-yl)-6-pyrrolidin-1-ylpyrido[3,4-d]pyrimidin-4-amine Chemical compound N1=CC2=CC(NC=3C4=CC(=NC=C4N=CN=3)N3CCCC3)=CC=C2N1CC1=CC=CC=C1 WVIYDZAMWSNDDO-UHFFFAOYSA-N 0.000 claims description 3
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 claims description 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 2
- SDNXQWUJWNTDCC-UHFFFAOYSA-N 2-methylsulfonylethanamine Chemical compound CS(=O)(=O)CCN SDNXQWUJWNTDCC-UHFFFAOYSA-N 0.000 claims description 2
- UUVCADJIKORGBL-UHFFFAOYSA-N CS(CCCNC(NCCCS(C)(=O)=O)N(CC(N)=O)NCCNS(C)(=O)=O)=O Chemical compound CS(CCCNC(NCCCS(C)(=O)=O)N(CC(N)=O)NCCNS(C)(=O)=O)=O UUVCADJIKORGBL-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052770 Uranium Inorganic materials 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 claims description 2
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 2
- KQSSATDQUYCRGS-UHFFFAOYSA-N methyl glycinate Chemical compound COC(=O)CN KQSSATDQUYCRGS-UHFFFAOYSA-N 0.000 claims description 2
- OXLINNZBULSARQ-UHFFFAOYSA-N n-(1-benzylindazol-5-yl)-6-(1,2,4-triazol-1-yl)pyrido[3,4-d]pyrimidin-4-amine Chemical compound N1=CC2=CC(NC=3C4=CC(=NC=C4N=CN=3)N3N=CN=C3)=CC=C2N1CC1=CC=CC=C1 OXLINNZBULSARQ-UHFFFAOYSA-N 0.000 claims description 2
- FRHWAVXLZREEEK-UHFFFAOYSA-N n-(1-benzylindazol-5-yl)-6-(5-methyl-1,3,4-oxadiazol-2-yl)pyrido[3,4-d]pyrimidin-4-amine Chemical compound O1C(C)=NN=C1C(N=CC1=NC=N2)=CC1=C2NC1=CC=C(N(CC=2C=CC=CC=2)N=C2)C2=C1 FRHWAVXLZREEEK-UHFFFAOYSA-N 0.000 claims description 2
- SSCPVPGCPUVKIU-UHFFFAOYSA-N n-(1-benzylindazol-5-yl)-6-(triazol-1-yl)pyrido[3,4-d]pyrimidin-4-amine Chemical compound N1=CC2=CC(NC=3C4=CC(=NC=C4N=CN=3)N3N=NC=C3)=CC=C2N1CC1=CC=CC=C1 SSCPVPGCPUVKIU-UHFFFAOYSA-N 0.000 claims description 2
- KLLXUSHFLQBLCW-UHFFFAOYSA-N n-(1-benzylindazol-5-yl)-6-(triazol-2-yl)pyrido[3,4-d]pyrimidin-4-amine Chemical compound N1=CC2=CC(NC=3C4=CC(=NC=C4N=CN=3)N3N=CC=N3)=CC=C2N1CC1=CC=CC=C1 KLLXUSHFLQBLCW-UHFFFAOYSA-N 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 125000005554 pyridyloxy group Chemical group 0.000 claims description 2
- 229910052727 yttrium Inorganic materials 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- QHJNXFUNGGUIDH-UHFFFAOYSA-N 6-chloropyrido[3,4-d]pyrimidin-4-amine Chemical compound N1=C(Cl)C=C2C(N)=NC=NC2=C1 QHJNXFUNGGUIDH-UHFFFAOYSA-N 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 175
- 239000000203 mixture Substances 0.000 description 57
- 239000007787 solid Substances 0.000 description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 35
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 235000019439 ethyl acetate Nutrition 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- QCEPAUUUYZXMGD-UHFFFAOYSA-N 4-chloro-n,n-dimethylpyrido[3,4-d]pyrimidin-6-amine Chemical compound N1=CN=C2C=NC(N(C)C)=CC2=C1Cl QCEPAUUUYZXMGD-UHFFFAOYSA-N 0.000 description 10
- 108060006698 EGF receptor Proteins 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- 150000001412 amines Chemical class 0.000 description 10
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000000377 silicon dioxide Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- BQUSMTPKYUILPD-UHFFFAOYSA-N 1-benzylindazol-5-amine Chemical compound N1=CC2=CC(N)=CC=C2N1CC1=CC=CC=C1 BQUSMTPKYUILPD-UHFFFAOYSA-N 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- UYDNPZLYDODKKA-UHFFFAOYSA-N 1-benzylindol-5-amine Chemical compound C1=CC2=CC(N)=CC=C2N1CC1=CC=CC=C1 UYDNPZLYDODKKA-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 5
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 101150093908 PDGFRB gene Proteins 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 108060006706 SRC Proteins 0.000 description 4
- 102000001332 SRC Human genes 0.000 description 4
- 230000001594 aberrant effect Effects 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 229960005141 piperazine Drugs 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- BTNPJMNKYNWUPD-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]indazol-5-amine Chemical compound N1=CC2=CC(N)=CC=C2N1CC1=CC=CC(F)=C1 BTNPJMNKYNWUPD-UHFFFAOYSA-N 0.000 description 3
- MACVPLPBEJHWHK-UHFFFAOYSA-N 1-benzyl-3-methyl-5-nitroindazole Chemical compound C12=CC=C([N+]([O-])=O)C=C2C(C)=NN1CC1=CC=CC=C1 MACVPLPBEJHWHK-UHFFFAOYSA-N 0.000 description 3
- LONPVIGEVNTHTN-UHFFFAOYSA-N 1-benzyl-5-nitroindole Chemical compound C1=CC2=CC([N+](=O)[O-])=CC=C2N1CC1=CC=CC=C1 LONPVIGEVNTHTN-UHFFFAOYSA-N 0.000 description 3
- XZNGFDIIMTUDLO-UHFFFAOYSA-N 2-(4-chloropyrido[3,4-d]pyrimidin-6-yl)-5-methyl-1,3,4-oxadiazole Chemical compound O1C(C)=NN=C1C1=CC2=C(Cl)N=CN=C2C=N1 XZNGFDIIMTUDLO-UHFFFAOYSA-N 0.000 description 3
- AMYYUKGKCJKCBI-UHFFFAOYSA-N 2-methylsulfonylethanamine;hydrochloride Chemical compound Cl.CS(=O)(=O)CCN AMYYUKGKCJKCBI-UHFFFAOYSA-N 0.000 description 3
- CKPNVNAKQGYUSK-UHFFFAOYSA-N 4,6-dichloropyrido[3,4-d]pyrimidine Chemical compound N1=CN=C2C=NC(Cl)=CC2=C1Cl CKPNVNAKQGYUSK-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 101150028321 Lck gene Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 3
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 125000000000 cycloalkoxy group Chemical group 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000013067 intermediate product Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 3
- 150000003246 quinazolines Chemical class 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 2
- BHOSCKKNURHTND-UHFFFAOYSA-N 1-(benzenesulfonyl)indol-5-amine Chemical compound C1=CC2=CC(N)=CC=C2N1S(=O)(=O)C1=CC=CC=C1 BHOSCKKNURHTND-UHFFFAOYSA-N 0.000 description 2
- LXFNLRHJSUSBFL-UHFFFAOYSA-N 1-(pyridin-2-ylmethyl)indazol-5-amine Chemical compound N1=CC2=CC(N)=CC=C2N1CC1=CC=CC=N1 LXFNLRHJSUSBFL-UHFFFAOYSA-N 0.000 description 2
- ZSFTXNIYPDDDSG-UHFFFAOYSA-N 1-(pyridin-3-ylmethyl)indazol-5-amine Chemical compound N1=CC2=CC(N)=CC=C2N1CC1=CC=CN=C1 ZSFTXNIYPDDDSG-UHFFFAOYSA-N 0.000 description 2
- KJRSYMJRLSJMOZ-UHFFFAOYSA-N 1-N,1-N-dimethyl-2H-pyridine-1,4-diamine Chemical compound CN(N1CC=C(C=C1)N)C KJRSYMJRLSJMOZ-UHFFFAOYSA-N 0.000 description 2
- HNAXFSKDGWBXFI-UHFFFAOYSA-N 1-[(2-fluorophenyl)methyl]indazol-5-amine Chemical compound N1=CC2=CC(N)=CC=C2N1CC1=CC=CC=C1F HNAXFSKDGWBXFI-UHFFFAOYSA-N 0.000 description 2
- VHWVWFPJTDRKIK-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]indazol-5-amine Chemical compound N1=CC2=CC(N)=CC=C2N1CC1=CC=C(F)C=C1 VHWVWFPJTDRKIK-UHFFFAOYSA-N 0.000 description 2
- NCALXEWOPBPBQR-UHFFFAOYSA-N 1-benzyl-3-methylindazol-5-amine Chemical compound C12=CC=C(N)C=C2C(C)=NN1CC1=CC=CC=C1 NCALXEWOPBPBQR-UHFFFAOYSA-N 0.000 description 2
- KACWEIWGSHNESJ-UHFFFAOYSA-N 1-benzyl-5-nitroindazole Chemical compound N1=CC2=CC([N+](=O)[O-])=CC=C2N1CC1=CC=CC=C1 KACWEIWGSHNESJ-UHFFFAOYSA-N 0.000 description 2
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 2
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 2
- SRLUJNCPQPGUKZ-UHFFFAOYSA-N 2-(dimethylamino)-5-(2,2-dimethylpropanoylamino)pyridine-4-carboxylic acid Chemical compound CN(C)C1=CC(C(O)=O)=C(NC(=O)C(C)(C)C)C=N1 SRLUJNCPQPGUKZ-UHFFFAOYSA-N 0.000 description 2
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- MQTBODNTRQAUSK-UHFFFAOYSA-N 2-benzyl-3h-benzimidazol-5-amine Chemical compound N1C2=CC(N)=CC=C2N=C1CC1=CC=CC=C1 MQTBODNTRQAUSK-UHFFFAOYSA-N 0.000 description 2
- UMWIVOZCYNITGG-UHFFFAOYSA-N 2-benzyl-6-nitro-1h-benzimidazole Chemical compound N1C2=CC([N+](=O)[O-])=CC=C2N=C1CC1=CC=CC=C1 UMWIVOZCYNITGG-UHFFFAOYSA-N 0.000 description 2
- SMNDYUVBFMFKNZ-UHFFFAOYSA-M 2-furoate Chemical compound [O-]C(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-M 0.000 description 2
- RNUNUPZAHSFZPH-UHFFFAOYSA-N 3-(benzenesulfonyl)-1h-indol-6-amine Chemical compound C=1NC2=CC(N)=CC=C2C=1S(=O)(=O)C1=CC=CC=C1 RNUNUPZAHSFZPH-UHFFFAOYSA-N 0.000 description 2
- KCGZHOPKWJEWIO-UHFFFAOYSA-N 4-(furan-2-yl)-1-methyl-3,5,8-trioxabicyclo[2.2.2]octane Chemical compound O1CC(C)(CO2)COC12C1=CC=CO1 KCGZHOPKWJEWIO-UHFFFAOYSA-N 0.000 description 2
- UCQOIQWWCPATPS-UHFFFAOYSA-N 4-chloro-6-phenylmethoxypyrido[3,4-d]pyrimidine Chemical compound C1=C2C(Cl)=NC=NC2=CN=C1OCC1=CC=CC=C1 UCQOIQWWCPATPS-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- HGWZRWMSONEISS-UHFFFAOYSA-N 4-n-(3-benzyl-2h-indazol-6-yl)-6-n,6-n-dimethylpyrido[3,4-d]pyrimidine-4,6-diamine Chemical compound N1=CN=C2C=NC(N(C)C)=CC2=C1NC(C=C1NN=2)=CC=C1C=2CC1=CC=CC=C1 HGWZRWMSONEISS-UHFFFAOYSA-N 0.000 description 2
- MXZQLVOKPYMZSH-UHFFFAOYSA-N 4-n-(3-benzylsulfonyl-2h-indazol-6-yl)-6-n,6-n-dimethylpyrido[3,4-d]pyrimidine-4,6-diamine Chemical compound N1=CN=C2C=NC(N(C)C)=CC2=C1NC(C=C1NN=2)=CC=C1C=2S(=O)(=O)CC1=CC=CC=C1 MXZQLVOKPYMZSH-UHFFFAOYSA-N 0.000 description 2
- PEXVJBCQKQZYOI-UHFFFAOYSA-N 5-amino-2-(dimethylamino)pyridine-4-carboxylic acid Chemical compound CN(C)C1=CC(C(O)=O)=C(N)C=N1 PEXVJBCQKQZYOI-UHFFFAOYSA-N 0.000 description 2
- VRNHWAZLHPUTSM-UHFFFAOYSA-N 6-(2h-tetrazol-5-yl)-1h-pyrido[3,4-d]pyrimidin-4-one Chemical compound C1=C2C(=O)NC=NC2=CN=C1C1=NN=NN1 VRNHWAZLHPUTSM-UHFFFAOYSA-N 0.000 description 2
- IVRTWLXZVOGNQN-UHFFFAOYSA-N 6-(5-methyl-1,3,4-oxadiazol-2-yl)-1h-pyrido[3,4-d]pyrimidin-4-one Chemical compound O1C(C)=NN=C1C1=CC(C(NC=N2)=O)=C2C=N1 IVRTWLXZVOGNQN-UHFFFAOYSA-N 0.000 description 2
- FOXGCSWJHNGAHI-UHFFFAOYSA-N 6-(dimethylamino)-1h-pyrido[3,4-d]pyrimidin-4-one Chemical compound N1=CNC(=O)C2=C1C=NC(N(C)C)=C2 FOXGCSWJHNGAHI-UHFFFAOYSA-N 0.000 description 2
- BBPUOYYUBFLNML-UHFFFAOYSA-N 6-chloro-1h-pyrido[3,4-d]pyrimidin-4-one Chemical compound N1=CNC(=O)C2=C1C=NC(Cl)=C2 BBPUOYYUBFLNML-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 101100503636 Danio rerio fyna gene Proteins 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101150018272 FYN gene Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- OBICOKSTJBXYFN-UHFFFAOYSA-N N,N-dimethyl-4-nitro-2H-pyridin-1-amine Chemical compound CN(N1CC=C(C=C1)[N+](=O)[O-])C OBICOKSTJBXYFN-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 2
- 229920003189 Nylon 4,6 Polymers 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 108091005682 Receptor kinases Proteins 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- DUNKZQKFWZSBHG-UHFFFAOYSA-N n-(1-benzylindol-5-yl)-6-chloropyrido[3,4-d]pyrimidin-4-amine Chemical compound N1=CN=C2C=NC(Cl)=CC2=C1NC(C=C1C=C2)=CC=C1N2CC1=CC=CC=C1 DUNKZQKFWZSBHG-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 238000003566 phosphorylation assay Methods 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 229910000080 stannane Inorganic materials 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- BCXOSCQTHVTUET-UHFFFAOYSA-N 1-(2-fluoro-5-nitrophenyl)ethanone Chemical compound CC(=O)C1=CC([N+]([O-])=O)=CC=C1F BCXOSCQTHVTUET-UHFFFAOYSA-N 0.000 description 1
- JXYVDGXOCFQXTF-UHFFFAOYSA-N 1-(pyridin-4-ylmethyl)indazol-5-amine Chemical compound N1=CC2=CC(N)=CC=C2N1CC1=CC=NC=C1 JXYVDGXOCFQXTF-UHFFFAOYSA-N 0.000 description 1
- DDCMQWDHBVDKHH-UHFFFAOYSA-N 1-[(2,3-difluorophenyl)methyl]indazol-5-amine Chemical compound N1=CC2=CC(N)=CC=C2N1CC1=CC=CC(F)=C1F DDCMQWDHBVDKHH-UHFFFAOYSA-N 0.000 description 1
- ZEGHCBNPNZAANE-UHFFFAOYSA-N 1-[(3,5-difluorophenyl)methyl]indazol-5-amine Chemical compound N1=CC2=CC(N)=CC=C2N1CC1=CC(F)=CC(F)=C1 ZEGHCBNPNZAANE-UHFFFAOYSA-N 0.000 description 1
- 125000004173 1-benzimidazolyl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N1* 0.000 description 1
- YDTDKKULPWTHRV-UHFFFAOYSA-N 1H-indazol-3-amine Chemical compound C1=CC=C2C(N)=NNC2=C1 YDTDKKULPWTHRV-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical group C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MAAXBKQABSWUKL-UHFFFAOYSA-N 2-[4-[4-[(1-benzylindazol-5-yl)amino]pyrido[3,4-d]pyrimidin-6-yl]piperazin-1-yl]-n-propan-2-ylacetamide Chemical compound C1CN(CC(=O)NC(C)C)CCN1C(N=CC1=NC=N2)=CC1=C2NC1=CC=C(N(CC=2C=CC=CC=2)N=C2)C2=C1 MAAXBKQABSWUKL-UHFFFAOYSA-N 0.000 description 1
- WOBMUXLADQPSBY-UHFFFAOYSA-N 2-benzyl-5-nitro-1,3-dihydroindazole Chemical compound C1C2=CC([N+](=O)[O-])=CC=C2NN1CC1=CC=CC=C1 WOBMUXLADQPSBY-UHFFFAOYSA-N 0.000 description 1
- LIEPVGBDUYKPLC-UHFFFAOYSA-N 2-chloro-4-nitropyridine Chemical compound [O-][N+](=O)C1=CC=NC(Cl)=C1 LIEPVGBDUYKPLC-UHFFFAOYSA-N 0.000 description 1
- QGKGASXQTBQINX-UHFFFAOYSA-N 3,4-dihydro-1h-pyrimidin-2-one Chemical compound O=C1NCC=CN1 QGKGASXQTBQINX-UHFFFAOYSA-N 0.000 description 1
- KQAODTJBTYIOOT-UHFFFAOYSA-N 3-(benzenesulfonyl)-6-nitro-1h-indole Chemical compound C=1NC2=CC([N+](=O)[O-])=CC=C2C=1S(=O)(=O)C1=CC=CC=C1 KQAODTJBTYIOOT-UHFFFAOYSA-N 0.000 description 1
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 description 1
- DBPKMSBWOKAKLA-UHFFFAOYSA-N 4-chloropyrimidine Chemical group ClC1=CC=NC=N1 DBPKMSBWOKAKLA-UHFFFAOYSA-N 0.000 description 1
- RAUWPNXIALNKQM-UHFFFAOYSA-N 4-nitro-1,2-phenylenediamine Chemical compound NC1=CC=C([N+]([O-])=O)C=C1N RAUWPNXIALNKQM-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- XMOBKRSGYZRORK-UHFFFAOYSA-N 5-[4-[(1-benzylindazol-5-yl)amino]pyrido[3,4-d]pyrimidin-6-yl]furan-2-carboxylic acid;hydrochloride Chemical compound Cl.O1C(C(=O)O)=CC=C1C(N=CC1=NC=N2)=CC1=C2NC1=CC=C(N(CC=2C=CC=CC=2)N=C2)C2=C1 XMOBKRSGYZRORK-UHFFFAOYSA-N 0.000 description 1
- WSGURAYTCUVDQL-UHFFFAOYSA-N 5-nitro-1h-indazole Chemical compound [O-][N+](=O)C1=CC=C2NN=CC2=C1 WSGURAYTCUVDQL-UHFFFAOYSA-N 0.000 description 1
- OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 1
- NUTUPYCNXAFILA-UHFFFAOYSA-N 6-chloro-1h-pyrido[3,4-d]pyrimidin-2-one Chemical compound C1=NC(=O)NC2=C1C=C(Cl)N=C2 NUTUPYCNXAFILA-UHFFFAOYSA-N 0.000 description 1
- OGOPAVRSPJYRLS-UHFFFAOYSA-N 6-chloropyrido[3,4-d]pyrimidine Chemical compound N1=CN=C2C=NC(Cl)=CC2=C1 OGOPAVRSPJYRLS-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 239000012425 OXONE® Substances 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000187419 Streptomyces rimosus Species 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- GCTFWCDSFPMHHS-UHFFFAOYSA-M Tributyltin chloride Chemical compound CCCC[Sn](Cl)(CCCC)CCCC GCTFWCDSFPMHHS-UHFFFAOYSA-M 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- XPOLVIIHTDKJRY-UHFFFAOYSA-N acetic acid;methanimidamide Chemical compound NC=N.CC(O)=O XPOLVIIHTDKJRY-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000002355 alkine group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000000320 amidine group Chemical group 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000003705 anilinocarbonyl group Chemical group O=C([*])N([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- MSJHOJKVMMEMNX-UHFFFAOYSA-N benzylhydrazine;hydron;dichloride Chemical compound Cl.Cl.NNCC1=CC=CC=C1 MSJHOJKVMMEMNX-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- XEVRDFDBXJMZFG-UHFFFAOYSA-N carbonyl dihydrazine Chemical compound NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical group C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000000062 cyclohexylmethoxy group Chemical group [H]C([H])(O*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000006317 cyclopropyl amino group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 1
- LIWAQLJGPBVORC-UHFFFAOYSA-N ethylmethylamine Chemical compound CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 150000002473 indoazoles Chemical class 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- WWAHWFCQESJGIU-UHFFFAOYSA-N n-(1-benzylindazol-5-yl)-6-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyrimidin-4-amine Chemical compound C1CN(C)CCN1C(N=CC1=NC=N2)=CC1=C2NC1=CC=C(N(CC=2C=CC=CC=2)N=C2)C2=C1 WWAHWFCQESJGIU-UHFFFAOYSA-N 0.000 description 1
- DFZVDCVWUGWYOF-UHFFFAOYSA-N n-(1-benzylindazol-5-yl)-6-(5-methyl-1,3,4-oxadiazol-2-yl)pyrido[3,4-d]pyrimidin-4-amine;hydrochloride Chemical compound Cl.O1C(C)=NN=C1C(N=CC1=NC=N2)=CC1=C2NC1=CC=C(N(CC=2C=CC=CC=2)N=C2)C2=C1 DFZVDCVWUGWYOF-UHFFFAOYSA-N 0.000 description 1
- RNCGDMXTBBJFEB-UHFFFAOYSA-N n-(1-benzylindazol-5-yl)-6-[5-(1-methyl-3,5,8-trioxabicyclo[2.2.2]octan-4-yl)furan-2-yl]pyrido[3,4-d]pyrimidin-4-amine Chemical compound O1CC(C)(CO2)COC12C(O1)=CC=C1C(N=CC1=NC=N2)=CC1=C2NC(C=C1C=N2)=CC=C1N2CC1=CC=CC=C1 RNCGDMXTBBJFEB-UHFFFAOYSA-N 0.000 description 1
- XCOAATZYXZVAHA-UHFFFAOYSA-N n-(1-benzylindazol-5-yl)-6-chloropyrido[3,4-d]pyrimidin-4-amine;hydrochloride Chemical compound Cl.N1=CN=C2C=NC(Cl)=CC2=C1NC(C=C1C=N2)=CC=C1N2CC1=CC=CC=C1 XCOAATZYXZVAHA-UHFFFAOYSA-N 0.000 description 1
- COGNCPVOUZUOSK-UHFFFAOYSA-N n-(1-benzylindazol-5-yl)pyrido[3,4-d]pyrimidin-4-amine Chemical compound N1=CC2=CC(NC=3C4=CC=NC=C4N=CN=3)=CC=C2N1CC1=CC=CC=C1 COGNCPVOUZUOSK-UHFFFAOYSA-N 0.000 description 1
- AWXQTMDKUGQPCQ-UHFFFAOYSA-N n-(1-benzylindol-5-yl)-6-chloropyrido[3,4-d]pyrimidin-4-amine;hydrochloride Chemical compound Cl.N1=CN=C2C=NC(Cl)=CC2=C1NC(C=C1C=C2)=CC=C1N2CC1=CC=CC=C1 AWXQTMDKUGQPCQ-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000001451 organic peroxides Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 159000000018 pyrido[2,3-d]pyrimidines Chemical class 0.000 description 1
- 150000008518 pyridopyrimidines Chemical class 0.000 description 1
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical class N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000009703 regulation of cell differentiation Effects 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- SANWDQJIWZEKOD-UHFFFAOYSA-N tributyl(furan-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CO1 SANWDQJIWZEKOD-UHFFFAOYSA-N 0.000 description 1
- OGYWKJKAIAEDQX-UHFFFAOYSA-N tributyl-(3-methylimidazol-4-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CN=CN1C OGYWKJKAIAEDQX-UHFFFAOYSA-N 0.000 description 1
- PIILXFBHQILWPS-UHFFFAOYSA-N tributyltin Chemical compound CCCC[Sn](CCCC)CCCC PIILXFBHQILWPS-UHFFFAOYSA-N 0.000 description 1
- JUDXOKKZTISQDJ-UHFFFAOYSA-N triphenylphosphane;hydrochloride Chemical compound Cl.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 JUDXOKKZTISQDJ-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9614763 | 1996-07-13 | ||
| GBGB9614763.2A GB9614763D0 (en) | 1996-07-13 | 1996-07-13 | Heterocyclic compounds |
| GB9625492 | 1996-12-07 | ||
| GBGB9625492.5A GB9625492D0 (en) | 1996-12-07 | 1996-12-07 | Heterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2206729T3 true ES2206729T3 (es) | 2004-05-16 |
Family
ID=26309694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97930518T Expired - Lifetime ES2206729T3 (es) | 1996-07-13 | 1997-07-11 | Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosina quinasa. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US6174889B1 (en:Method) |
| EP (2) | EP0912570B1 (en:Method) |
| JP (1) | JP2000514445A (en:Method) |
| KR (1) | KR20000023812A (en:Method) |
| CN (1) | CN1230187A (en:Method) |
| AP (1) | AP9901434A0 (en:Method) |
| AR (1) | AR007856A1 (en:Method) |
| AT (1) | ATE249458T1 (en:Method) |
| AU (1) | AU3443997A (en:Method) |
| BR (1) | BR9710359A (en:Method) |
| CA (1) | CA2260061A1 (en:Method) |
| CZ (1) | CZ8999A3 (en:Method) |
| DE (1) | DE69724789T2 (en:Method) |
| EA (1) | EA199900022A1 (en:Method) |
| ES (1) | ES2206729T3 (en:Method) |
| HR (1) | HRP970371A2 (en:Method) |
| ID (1) | ID19403A (en:Method) |
| IL (1) | IL127796A0 (en:Method) |
| IS (1) | IS4939A (en:Method) |
| NO (1) | NO990124L (en:Method) |
| PE (1) | PE91198A1 (en:Method) |
| PL (1) | PL331221A1 (en:Method) |
| TR (1) | TR199900049T2 (en:Method) |
| WO (1) | WO1998002438A1 (en:Method) |
| YU (1) | YU1099A (en:Method) |
Families Citing this family (296)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK285141B6 (sk) | 1996-02-13 | 2006-07-07 | Astrazeneca Uk Limited | Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje |
| ATE211134T1 (de) | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| PL340589A1 (en) | 1997-11-11 | 2001-02-12 | Pfizer Prod Inc | Derivatives of thienepyrimidine and thienepyridine useful as anticarcinogenic agents |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| KR100415791B1 (ko) | 1998-06-19 | 2004-01-24 | 화이자 프로덕츠 인코포레이티드 | 피롤로[2,3-디]피리미딘 화합물 |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| BRPI9914164B8 (pt) | 1998-09-29 | 2021-05-25 | American Cyanamid Co | compostos de 3-ciano quinolina |
| US6288082B1 (en) | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| AU763669B2 (en) * | 1998-09-29 | 2003-07-31 | Wyeth Holdings Corporation | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
| US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US7625859B1 (en) | 2000-02-16 | 2009-12-01 | Oregon Health & Science University | HER-2 binding antagonists |
| US7393823B1 (en) | 1999-01-20 | 2008-07-01 | Oregon Health And Science University | HER-2 binding antagonists |
| US7396810B1 (en) | 2000-08-14 | 2008-07-08 | Oregon Health Sciences University | Compositions and methods for treating cancer by modulating HER-2 and EGF receptors |
| UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| GB9914486D0 (en) | 1999-06-21 | 1999-08-18 | Smithkline Beecham Plc | Medicaments |
| US6933299B1 (en) | 1999-07-09 | 2005-08-23 | Smithkline Beecham Corporation | Anilinoquinazolines as protein tyrosine kinase inhibitors |
| DE60037020T2 (de) | 1999-07-09 | 2008-08-21 | Glaxo Group Ltd., Greenford | Anilinochinazoline als protein-tyrosin-kinasehemmer |
| GB9917406D0 (en) | 1999-07-23 | 1999-09-22 | Smithkline Beecham Plc | Compounds |
| GB9917408D0 (en) | 1999-07-23 | 1999-09-22 | Smithkline Beecham Plc | Compounds |
| US6432979B1 (en) | 1999-08-12 | 2002-08-13 | American Cyanamid Company | Method of treating or inhibiting colonic polyps and colorectal cancer |
| HU229414B1 (hu) | 1999-11-05 | 2013-12-30 | Astrazeneca Ab | Kinazolin-származékok mint VEGF-inhibitorok, eljárás az elõállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
| UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| UA75055C2 (uk) * | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| NZ518884A (en) | 1999-12-10 | 2004-02-27 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidine compounds |
| US6610688B2 (en) | 1999-12-21 | 2003-08-26 | Sugen, Inc. | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| DK1686130T3 (da) | 2000-06-26 | 2009-04-06 | Pfizer Prod Inc | Pyrrolo-[2,3-d]-pyrimidinforbindelser som immunsuppressive midler |
| ATE353891T1 (de) * | 2000-06-30 | 2007-03-15 | Glaxo Group Ltd | Ditosylatsalze von chinazolinverbindungen |
| JP2004504397A (ja) * | 2000-07-26 | 2004-02-12 | スミスクライン ビーチャム パブリック リミテッド カンパニー | 抗菌活性を有するアミノピペリジンキノリン類およびそれらのアザイソステリックアナログ類 |
| EP1311500A2 (en) * | 2000-08-09 | 2003-05-21 | AstraZeneca AB | Indole, azaindole and indazole derivatives having vegf inhibiting activity |
| US7547702B2 (en) | 2000-09-20 | 2009-06-16 | Ortho-Mcneil Pharmaceutical, Inc. | 4-amino-quinazolines |
| DE60126997T2 (de) | 2000-10-20 | 2007-10-25 | Eisai R&D Management Co., Ltd. | Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen |
| EP2796468A2 (en) | 2001-01-05 | 2014-10-29 | Pfizer Inc | Antibodies to insulin-like growth factor I receptor |
| EP1353693B1 (en) | 2001-01-16 | 2005-03-16 | Glaxo Group Limited | Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer |
| GB0101577D0 (en) | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
| ATE330956T1 (de) * | 2001-04-13 | 2006-07-15 | Pfizer Prod Inc | Bizyklisch substituierte 4- aminopyridopyrimidinderivate |
| GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| GB0112836D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| WO2003000194A2 (en) | 2001-06-21 | 2003-01-03 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
| US7829566B2 (en) | 2001-09-17 | 2010-11-09 | Werner Mederski | 4-amino-quinazolines |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| JP4505228B2 (ja) * | 2002-01-10 | 2010-07-21 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | Ｒｈｏ−キナーゼ阻害剤 |
| JP2005526714A (ja) * | 2002-01-17 | 2005-09-08 | ニューロジェン・コーポレーション | カプサイシンのモジュレーターとしての置換キナゾリン−４−イルアミン類縁体 |
| ES2298497T3 (es) | 2002-01-23 | 2008-05-16 | Bayer Pharmaceuticals Corporation | Inhibidores de quinasa rho. |
| CA2473510A1 (en) | 2002-01-23 | 2003-07-31 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives as rho-kinase inhibitors |
| JP4508650B2 (ja) | 2002-01-29 | 2010-07-21 | グラクソ グループ リミテッド | アミノピペリジン化合物、当該化合物の製法および当該化合物を含有する医薬組成物 |
| JP4445753B2 (ja) | 2002-01-29 | 2010-04-07 | グラクソ グループ リミテッド | アミノピペリジン誘導体 |
| WO2003074529A2 (en) | 2002-03-01 | 2003-09-12 | Pfizer Inc. | iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS |
| JP2005534623A (ja) * | 2002-04-08 | 2005-11-17 | スミスクライン ビーチャム コーポレーション | Ｅｒｂファミリーの阻害剤並びにｒａｆ及び／又はｒａｓ阻害剤を投与することを含む癌の治療法 |
| UA77303C2 (en) | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
| EP2277867B1 (en) | 2002-07-15 | 2012-12-05 | Symphony Evolution, Inc. | Compounds, pharmaceutical compositions thereof and their use in treating cancer |
| CA2509821A1 (en) * | 2002-07-15 | 2004-01-22 | Janssen Pharmaceutica N.V. | 3-phenyl analogs of toxoflavine as kinase inhibitors |
| AU2003250701A1 (en) * | 2002-07-31 | 2004-02-16 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
| US7629347B2 (en) * | 2002-10-09 | 2009-12-08 | Critical Outcome Technologies, Inc. | Protein tyrosine kinase inhibitors |
| FR2846657B1 (fr) * | 2002-11-05 | 2004-12-24 | Servier Lab | Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP1567506A4 (en) | 2002-11-20 | 2007-06-20 | Array Biopharma Inc | CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR |
| MXPA05005576A (es) | 2002-11-26 | 2005-07-27 | Pfizer Prod Inc | Procedimiento de tratamiento del rechazo a un trasplante. |
| AU2003300898A1 (en) * | 2002-12-13 | 2004-07-09 | Neurogen Corporation | Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators |
| SI1585743T1 (sl) | 2002-12-19 | 2007-08-31 | Pfizer | Spojine 2-(1H-indazol-6-ilamino)-benzamida kot inhibitorji protein-kinaz, uporabnih pri zdravljenju očesnih bolezni |
| DK1625121T3 (da) | 2002-12-20 | 2010-05-10 | Pfizer Prod Inc | Pyrimidinderivater til behandling af abnorm cellevækst |
| ES2502490T3 (es) | 2003-02-26 | 2014-10-03 | Sugen, Inc. | Compuestos aminoheteroarílicos como inhibidores de proteín quinasas |
| JP2007525187A (ja) * | 2003-05-16 | 2007-09-06 | レセプター・バイオロジクス・インコーポレイテッド | イントロン融合タンパク質、ならびにその同定方法および使用方法 |
| TW200510373A (en) * | 2003-07-14 | 2005-03-16 | Neurogen Corp | Substituted quinolin-4-ylamine analogues |
| US7329664B2 (en) * | 2003-07-16 | 2008-02-12 | Neurogen Corporation | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues |
| US7008953B2 (en) | 2003-07-30 | 2006-03-07 | Agouron Pharmaceuticals, Inc. | 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| WO2005011607A2 (en) * | 2003-08-01 | 2005-02-10 | Smithkline Beecham Corporation | Treatment of cancers expressing p95 erbb2 |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| US20050038047A1 (en) * | 2003-08-14 | 2005-02-17 | Edwards Paul John | Azaquinazoline derivatives |
| MXPA06002296A (es) | 2003-08-29 | 2006-05-22 | Pfizer | Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos. |
| CA2537883A1 (en) * | 2003-09-09 | 2005-03-17 | Neurogen Corporation | Substituted bicyclic quinazolin-4-ylamine derivatives |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| PL2392565T3 (pl) | 2003-09-26 | 2014-08-29 | Exelixis Inc | Modulatory c-Met i sposoby stosowania |
| US7683172B2 (en) | 2003-11-11 | 2010-03-23 | Eisai R&D Management Co., Ltd. | Urea derivative and process for preparing the same |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| ATE473967T1 (de) * | 2003-11-26 | 2010-07-15 | Pfizer Prod Inc | Aminopyrazolderivate als gsk-3-inhibitoren |
| WO2005063739A1 (en) | 2003-12-23 | 2005-07-14 | Pfizer Inc. | Novel quinoline derivatives |
| TW200529846A (en) | 2004-02-20 | 2005-09-16 | Wyeth Corp | 3-quinolinecarbonitrile protein kinase inhibitors |
| KR20080095915A (ko) | 2004-05-06 | 2008-10-29 | 워너-램버트 캄파니 엘엘씨 | 4-페닐아미노-퀴나졸린-6-일-아미드 |
| WO2005113596A2 (en) * | 2004-05-14 | 2005-12-01 | Receptor Biologix, Inc. | Cell surface receptor isoforms and methods of identifying and using the same |
| WO2005120509A1 (en) * | 2004-06-04 | 2005-12-22 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| EP2322215A3 (en) | 2004-07-16 | 2011-09-28 | Pfizer Products Inc. | Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody |
| NZ552866A (en) | 2004-08-26 | 2010-06-25 | Pfizer | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
| US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
| CA2583230A1 (en) * | 2004-10-05 | 2006-04-20 | Oregon Health And Science University | Compositions and methods for treating disease |
| TW200621251A (en) | 2004-10-12 | 2006-07-01 | Neurogen Corp | Substituted biaryl quinolin-4-ylamine analogues |
| ATE501148T1 (de) | 2004-12-14 | 2011-03-15 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
| GB0428475D0 (en) * | 2004-12-30 | 2005-02-02 | 4 Aza Bioscience Nv | Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
| RU2413735C2 (ru) | 2005-03-31 | 2011-03-10 | Эдженсис, Инк. | Антитела и родственные молекулы, связывающиеся с белками 161p2f10b |
| KR100990027B1 (ko) | 2005-04-26 | 2010-10-26 | 화이자 인코포레이티드 | Ｐ-카드헤린 항체 |
| US20090170769A1 (en) * | 2005-05-13 | 2009-07-02 | Pei Jin | Cell surface receptor isoforms and methods of identifying and using the same |
| CA2612788A1 (en) * | 2005-06-24 | 2006-12-28 | Steven Cesar Alfons De Jonghe | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c |
| JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| TW200804345A (en) | 2005-08-30 | 2008-01-16 | Novartis Ag | Substituted benzimidazoles and methods of preparation |
| PT1933871E (pt) | 2005-09-07 | 2013-07-17 | Pfizer | Anticorpos monoclonais humanos para cinase-1 do tipo receptor de activina |
| ATE533057T1 (de) | 2005-09-20 | 2011-11-15 | Osi Pharm Inc | Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren |
| US7820683B2 (en) | 2005-09-20 | 2010-10-26 | Astrazeneca Ab | 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer |
| NZ569817A (en) | 2005-12-21 | 2011-10-28 | Abbott Lab | Anti-viral compounds |
| EP1971611B1 (en) | 2005-12-21 | 2012-10-10 | Abbott Laboratories | Anti-viral compounds |
| CA2633760A1 (en) | 2005-12-21 | 2007-07-05 | Abbott Laboratories | Anti-viral compounds |
| WO2007095124A2 (en) * | 2006-02-10 | 2007-08-23 | Transtech Pharma, Inc. | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors |
| WO2007098086A2 (en) * | 2006-02-17 | 2007-08-30 | Avalon Pharmaceuticals | Hydroxypiperidine derivatives and uses thereof |
| UA91129C2 (ru) | 2006-05-09 | 2010-06-25 | Пфайзер Продактс Инк. | Производные циклоалкиламинокислот и фармацевтическая композиция, которая их содержит |
| JP5190361B2 (ja) | 2006-05-18 | 2013-04-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 甲状腺癌に対する抗腫瘍剤 |
| KR100760148B1 (ko) | 2006-07-19 | 2007-09-18 | 주식회사 엘지생활건강 | 알파-리포산을 안정화시킨 화장료 조성물 |
| US8338435B2 (en) * | 2006-07-20 | 2012-12-25 | Gilead Sciences, Inc. | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections |
| WO2008016123A1 (en) * | 2006-08-03 | 2008-02-07 | Takeda Pharmaceutical Company Limited | GSK-3β INHIBITOR |
| CN101511793B (zh) | 2006-08-28 | 2011-08-03 | 卫材R&D管理有限公司 | 针对未分化型胃癌的抗肿瘤剂 |
| WO2008067119A2 (en) * | 2006-11-27 | 2008-06-05 | Smithkline Beecham Corporation | Novel compounds |
| US8236950B2 (en) | 2006-12-20 | 2012-08-07 | Abbott Laboratories | Anti-viral compounds |
| TW200840584A (en) * | 2006-12-26 | 2008-10-16 | Gilead Sciences Inc | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
| WO2008077649A1 (en) * | 2006-12-26 | 2008-07-03 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyrimidines useful for treating viral infectons |
| US8637531B2 (en) * | 2006-12-26 | 2014-01-28 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyridmidines useful for treating viral infections |
| US8034815B2 (en) | 2007-01-11 | 2011-10-11 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
| WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
| CA2684470C (en) * | 2007-04-16 | 2016-02-09 | Hutchison Medipharma Enterprises Limited | Pyrimidine derivatives |
| ES2593486T3 (es) | 2007-04-18 | 2016-12-09 | Pfizer Products Inc. | Derivados de sulfonil amida para el tratamiento del crecimiento celular anómalo |
| JP2010527915A (ja) * | 2007-04-26 | 2010-08-19 | アバロン ファーマシューティカルズ，インコーポレイテッド | 多重環化合物及びその用途 |
| WO2008139288A2 (en) * | 2007-05-09 | 2008-11-20 | Pfizer Inc. | Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials |
| EP2185574B1 (en) | 2007-09-07 | 2013-05-08 | Agensys, Inc. | Antibodies and related molecules that bind to 24p4c12 proteins |
| US8080558B2 (en) | 2007-10-29 | 2011-12-20 | Natco Pharma Limited | 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent |
| EP2218712B1 (en) | 2007-11-09 | 2015-07-01 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| WO2009079797A1 (en) | 2007-12-26 | 2009-07-02 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
| US20110092452A1 (en) * | 2008-03-05 | 2011-04-21 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating pancreatic cancer |
| CN112079769A (zh) * | 2008-04-23 | 2020-12-15 | 里格尔药品股份有限公司 | 用于治疗代谢障碍的甲酰胺化合物 |
| US7829574B2 (en) | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
| US8426430B2 (en) * | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
| WO2010002998A1 (en) * | 2008-07-03 | 2010-01-07 | Gilead Sciences, Inc. | 2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS |
| CA2999321A1 (en) | 2008-07-17 | 2010-01-21 | Critical Outcome Technologies Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| ES2432414T3 (es) * | 2008-08-12 | 2013-12-03 | Glaxosmithkline Llc | Compuestos químicos |
| CN102131812B (zh) | 2008-08-20 | 2014-04-09 | 硕腾有限责任公司 | 吡咯并[2，3-d]嘧啶化合物 |
| US7737157B2 (en) * | 2008-08-29 | 2010-06-15 | Hutchison Medipharma Enterprises Limited | Pyrimidine compounds |
| WO2010036917A1 (en) * | 2008-09-26 | 2010-04-01 | Takeda Pharmaceutical Company Limited | Prevention and treatment of cancer with ras gene mutation |
| WO2010036928A1 (en) * | 2008-09-26 | 2010-04-01 | Takeda Pharmaceutical Company Limited | Prevention and treatment of cancer with lkb1 non-expression (deletion or mutation) |
| US8476410B2 (en) | 2008-10-16 | 2013-07-02 | University of Pittsburgh—of the Commonwealth System of Higher Education | Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof |
| EP2349235A1 (en) | 2008-11-07 | 2011-08-03 | Triact Therapeutics, Inc. | Use of catecholic butane derivatives in cancer therapy |
| CN101735200B (zh) * | 2008-11-17 | 2013-01-02 | 岑均达 | 喹唑啉类化合物 |
| TWI511956B (zh) | 2009-01-16 | 2015-12-11 | Exelixis Inc | 製備ｎ-（４-｛〔６，７-雙（甲氧基）喹啉-４-基〕氧基｝苯基）-ｎ’-（４-氟苯基）環丙烷-１，１-二甲醯胺之方法 |
| WO2010090764A1 (en) | 2009-02-09 | 2010-08-12 | Supergen, Inc. | Pyrrolopyrimidinyl axl kinase inhibitors |
| WO2010099139A2 (en) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
| JP2012519170A (ja) | 2009-02-26 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法 |
| TW201035088A (en) | 2009-02-27 | 2010-10-01 | Supergen Inc | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors |
| JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| JP2012520893A (ja) | 2009-03-18 | 2012-09-10 | オーエスアイ・ファーマシューティカルズ，エルエルシー | Ｅｇｆｒ阻害薬及びｉｇｆ−１ｒ阻害剤の投与を含む組み合わせ癌治療 |
| CN106148547A (zh) | 2009-07-13 | 2016-11-23 | 霍夫曼-拉罗奇有限公司 | 用于癌症治疗的诊断方法和组合物 |
| WO2011014726A1 (en) | 2009-07-31 | 2011-02-03 | Osi Pharmaceuticals, Inc. | Mtor inhibitor and angiogenesis inhibitor combination therapy |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| WO2011021597A1 (ja) | 2009-08-19 | 2011-02-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体含有医薬組成物 |
| JP2013503846A (ja) | 2009-09-01 | 2013-02-04 | ファイザー・インク | ベンズイミダゾール誘導体 |
| CN102597776A (zh) | 2009-09-11 | 2012-07-18 | 霍夫曼-拉罗奇有限公司 | 鉴定响应抗癌剂的可能性升高的患者的方法 |
| US20110064732A1 (en) | 2009-09-17 | 2011-03-17 | Sanne Lysbet De Haas | Methods and compositions for diagnostic use in cancer patients |
| EA029273B1 (ru) | 2009-10-29 | 2018-03-30 | Джиноско | Киназные ингибиторы |
| CA2780875A1 (en) | 2009-11-13 | 2011-05-19 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
| WO2011073521A1 (en) | 2009-12-15 | 2011-06-23 | Petri Salven | Methods for enriching adult-derived endothelial progenitor cells and uses thereof |
| EP3597651A1 (en) | 2010-02-12 | 2020-01-22 | Pfizer Inc | Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one |
| AU2011223643A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| AU2011223655A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| WO2011120153A1 (en) | 2010-04-01 | 2011-10-06 | Critical Outcome Technologies Inc. | Compounds and method for treatment of hiv |
| WO2011153224A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
| EP3135692B8 (en) | 2010-06-16 | 2019-03-20 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Antibodies to endoplasmin and their use |
| USRE46511E1 (en) | 2010-06-23 | 2017-08-15 | Hanmi Science Co., Ltd. | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
| BR112012032462A2 (pt) | 2010-06-25 | 2016-11-08 | Eisai R&D Man Co Ltd | agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase. |
| SG187119A1 (en) | 2010-07-19 | 2013-02-28 | Hoffmann La Roche | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| BR112012033162A2 (pt) | 2010-07-19 | 2016-10-25 | Hoffmann La Roche | método de identificação de pacientes, método de previsão da capacidade de reação de pacientes, método de determinação da probabilidade de um paciente com câncer exibir benefícios de terapia anticâncer, método de otimização da eficácia terapêutica, método de tratamento de câncer, kit e conjunto de compostos |
| CA2806921C (en) | 2010-07-23 | 2019-11-26 | Trustees Of Boston University | Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery |
| WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
| EP2630134B9 (en) | 2010-10-20 | 2018-04-18 | Pfizer Inc | Pyridine-2- derivatives as smoothened receptor modulators |
| EP2468883A1 (en) | 2010-12-22 | 2012-06-27 | Pangaea Biotech S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
| US9134297B2 (en) | 2011-01-11 | 2015-09-15 | Icahn School Of Medicine At Mount Sinai | Method and compositions for treating cancer and related methods |
| US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
| EP2492688A1 (en) | 2011-02-23 | 2012-08-29 | Pangaea Biotech, S.A. | Molecular biomarkers for predicting response to antitumor treatment in lung cancer |
| WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
| US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
| US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| EP2699598B1 (en) | 2011-04-19 | 2019-03-06 | Pfizer Inc | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
| JP2014519813A (ja) | 2011-04-25 | 2014-08-21 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用 |
| ES2705950T3 (es) | 2011-06-03 | 2019-03-27 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib |
| US9416132B2 (en) | 2011-07-21 | 2016-08-16 | Tolero Pharmaceuticals, Inc. | Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors |
| CA2845179A1 (en) | 2011-08-31 | 2013-03-07 | Genentech, Inc. | Diagnostic markers |
| BR112014006840A2 (pt) | 2011-09-22 | 2017-04-04 | Pfizer | derivados de pirrolopirimidina e purina |
| EP2761025A1 (en) | 2011-09-30 | 2014-08-06 | Genentech, Inc. | Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells |
| US9783613B2 (en) | 2011-10-04 | 2017-10-10 | Igem Therapeutics Limited | IgE anti-HMW-MAA antibody |
| RU2014114015A (ru) | 2011-11-08 | 2015-12-20 | Пфайзер Инк. | Способы лечения воспалительных расстройств с использованием антител против m-csf |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| WO2013190089A1 (en) | 2012-06-21 | 2013-12-27 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting outcome in lung cancer |
| US9394257B2 (en) | 2012-10-16 | 2016-07-19 | Tolero Pharmaceuticals, Inc. | PKM2 modulators and methods for their use |
| US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| CN104755463A (zh) | 2012-12-21 | 2015-07-01 | 卫材R&D管理有限公司 | 非晶态形式的喹啉衍生物及其生产方法 |
| EP2961412A4 (en) | 2013-02-26 | 2016-11-09 | Triact Therapeutics Inc | CANCER THERAPY |
| RU2019119893A (ru) | 2013-03-14 | 2019-08-09 | Толеро Фармасьютикалз, Инк. | Ингибиторы jak2 и alk2 и способы их использования |
| HRP20171609T1 (hr) * | 2013-03-15 | 2017-12-15 | Quanticel Pharmaceuticals Inc | Inhibitori histon demetilaze |
| WO2014147246A1 (en) | 2013-03-21 | 2014-09-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression |
| US9206188B2 (en) | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
| JP6411379B2 (ja) | 2013-05-14 | 2018-10-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー |
| AR096654A1 (es) | 2013-06-20 | 2016-01-27 | Ab Science | Derivados de benzimidazol como inhibidores selectivos de proteína quinasa |
| US9381246B2 (en) | 2013-09-09 | 2016-07-05 | Triact Therapeutics, Inc. | Cancer therapy |
| UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
| PT3126528T (pt) | 2014-04-04 | 2021-09-09 | Crown Bioscience Inc Taicang | Métodos para determinar a responsividade a inibidores de mek/erk |
| WO2015155624A1 (en) | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dihydropyrrolopyrimidine derivatives |
| WO2015156674A2 (en) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| ES2759434T3 (es) | 2014-04-30 | 2020-05-11 | Pfizer | Derivados de diheterociclo unidos a cicloalquilo |
| WO2016001789A1 (en) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer |
| JP6811706B2 (ja) | 2014-07-31 | 2021-01-13 | ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー | Ｅｐｈａ４に対するヒトモノクローナル抗体及びそれらの使用 |
| DK3524595T3 (da) | 2014-08-28 | 2022-09-19 | Eisai R&D Man Co Ltd | Quinolinderivat af høj renhed og fremgangsmåde til fremstilling deraf |
| JP6621477B2 (ja) | 2014-12-18 | 2019-12-18 | ファイザー・インク | ピリミジンおよびトリアジン誘導体ならびにａｘｌ阻害薬としてのそれらの使用 |
| JP6900314B2 (ja) | 2014-12-24 | 2021-07-07 | ジェネンテック， インコーポレイテッド | 膀胱癌の治療、診断、及び予後判定方法 |
| DK3263106T3 (da) | 2015-02-25 | 2024-01-08 | Eisai R&D Man Co Ltd | Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat |
| WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| US9901574B2 (en) | 2015-04-20 | 2018-02-27 | Tolero Pharmaceuticals, Inc. | Predicting response to alvocidib by mitochondrial profiling |
| CN107709344B (zh) | 2015-05-01 | 2022-07-15 | 共晶制药股份有限公司 | 用于治疗黄病毒科病毒和癌症的核苷类似物 |
| EP3527574B1 (en) | 2015-05-18 | 2022-04-06 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs having increased bioavailability |
| US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
| WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
| US10568887B2 (en) | 2015-08-03 | 2020-02-25 | Tolero Pharmaceuticals, Inc. | Combination therapies for treatment of cancer |
| MX381976B (es) | 2015-08-20 | 2025-03-13 | Eisai R&D Man Co Ltd | Agente terapéutico contra tumores. |
| SG11201804360XA (en) | 2015-12-03 | 2018-06-28 | Agios Pharmaceuticals Inc | Mat2a inhibitors for treating mtap null cancer |
| US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| CN110234659A (zh) | 2016-12-19 | 2019-09-13 | 特雷罗药物股份有限公司 | 用于敏感性分析的分析肽和方法 |
| SG11201906223TA (en) | 2016-12-22 | 2019-08-27 | Amgen Inc | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
| WO2018147275A1 (ja) | 2017-02-08 | 2018-08-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| CA3061888A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| EP4403175A3 (en) | 2017-09-08 | 2024-10-02 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
| WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
| US20200237766A1 (en) | 2017-10-13 | 2020-07-30 | Tolero Pharmaceuticals, Inc. | Pkm2 activators in combination with reactive oxygen species for treatment of cancer |
| JP7361722B2 (ja) | 2018-05-04 | 2023-10-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤及び同一物の使用方法 |
| MA52501A (fr) | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| CA3099045A1 (en) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
| MX2020012731A (es) | 2018-06-01 | 2021-02-22 | Amgen Inc | Inhibidores de kras g12c y metodos para su uso. |
| MX2020012204A (es) | 2018-06-11 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c para tratar el cáncer. |
| MX2020012261A (es) | 2018-06-12 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer. |
| KR20210038906A (ko) | 2018-07-26 | 2021-04-08 | 스미토모 다이니폰 파마 온콜로지, 인크. | 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제 |
| SG11202102679QA (en) | 2018-09-18 | 2021-04-29 | Nikang Therapeutics Inc | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
| EP3860608A1 (en) | 2018-10-04 | 2021-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| WO2020106640A1 (en) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| JP2022511029A (ja) | 2018-12-04 | 2022-01-28 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | がんの処置のための薬剤としての使用のためのｃｄｋ９インヒビターおよびその多形 |
| US12441705B2 (en) | 2018-12-20 | 2025-10-14 | Amgen Inc. | KIF18A inhibitors |
| MX2021007104A (es) | 2018-12-20 | 2021-08-11 | Amgen Inc | Inhibidores de kif18a. |
| TWI844602B (zh) | 2018-12-20 | 2024-06-11 | 美商安進公司 | Kif18a抑制劑 |
| WO2020132653A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| NL2022471B1 (en) | 2019-01-29 | 2020-08-18 | Vationpharma B V | Solid state forms of oclacitinib |
| WO2020167990A1 (en) | 2019-02-12 | 2020-08-20 | Tolero Pharmaceuticals, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
| JP2022522777A (ja) | 2019-03-01 | 2022-04-20 | レボリューション メディシンズ インコーポレイテッド | 二環式ヘテロアリール化合物及びその使用 |
| AU2020232616A1 (en) | 2019-03-01 | 2021-09-09 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
| WO2020191326A1 (en) | 2019-03-20 | 2020-09-24 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (aml) with venetoclax failure |
| WO2020198077A1 (en) | 2019-03-22 | 2020-10-01 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| CN118834208A (zh) | 2019-05-21 | 2024-10-25 | 美国安进公司 | 固态形式 |
| MX2022001302A (es) | 2019-08-02 | 2022-03-02 | Amgen Inc | Inhibidores de kif18a. |
| ES3051917T3 (en) | 2019-08-02 | 2025-12-30 | Amgen Inc | Kif18a inhibitors |
| CA3147451A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| MX2022001296A (es) | 2019-08-02 | 2022-02-22 | Amgen Inc | Inhibidores de kif18a. |
| EP4048671A1 (en) | 2019-10-24 | 2022-08-31 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
| JP2022553858A (ja) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | Ｒａｓ阻害剤 |
| MX2022005357A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| CN114867735A (zh) | 2019-11-04 | 2022-08-05 | 锐新医药公司 | Ras抑制剂 |
| KR20220100903A (ko) | 2019-11-08 | 2022-07-18 | 레볼루션 메디슨즈, 인크. | 이환식 헤테로아릴 화합물 및 이의 용도 |
| EP4058432A1 (en) | 2019-11-14 | 2022-09-21 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
| CN114728960B (zh) | 2019-11-14 | 2025-05-27 | 美国安进公司 | Kras g12c抑制剂化合物的改善的合成 |
| EP4065231A1 (en) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| TW202140011A (zh) | 2020-01-07 | 2021-11-01 | 美商銳新醫藥公司 | Shp2抑制劑給藥和治療癌症的方法 |
| WO2021155006A1 (en) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibitors of cyclin-dependent kinases and uses thereof |
| BR112022025550A2 (pt) | 2020-06-18 | 2023-03-07 | Revolution Medicines Inc | Métodos para retardar, prevenir e tratar resistência adquirida aos inibidores de ras |
| KR20230081726A (ko) | 2020-09-03 | 2023-06-07 | 레볼루션 메디슨즈, 인크. | Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도 |
| TW202227460A (zh) | 2020-09-15 | 2022-07-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| TW202241885A (zh) | 2020-12-22 | 2022-11-01 | 大陸商上海齊魯銳格醫藥研發有限公司 | Ｓｏｓ１抑制劑及其用途 |
| PE20240327A1 (es) | 2021-04-13 | 2024-02-22 | Nuvalent Inc | Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr |
| MX2023013085A (es) | 2021-05-05 | 2023-11-16 | Revolution Medicines Inc | Inhibidores de ras. |
| US12252497B2 (en) | 2021-05-05 | 2025-03-18 | Revolution Medicines, Inc. | Ras inhibitors |
| JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ｒａｓ阻害剤及びその使用 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| MX2024010828A (es) | 2022-03-07 | 2024-09-17 | Amgen Inc | Procedimiento para preparar 4-metil-2-propan-2-il-piridin-3-carbon itrilo. |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| AU2023285116A1 (en) | 2022-06-10 | 2024-12-19 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CR20250141A (es) | 2022-10-14 | 2025-05-26 | Black Diamond Therapeutics Inc | Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| TW202448897A (zh) | 2023-04-14 | 2024-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法 |
| WO2024216016A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025137507A1 (en) | 2023-12-22 | 2025-06-26 | Regor Pharmaceuticals, Inc. | Sos1 inhibitors and uses thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR5600M (en:Method) * | 1966-07-19 | 1968-01-08 | ||
| CA2083688A1 (en) * | 1990-05-25 | 1991-11-26 | Marc Lippman | Growth factor which inhibits the growth of cells overexpressing the human oncogene erbb-2 |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| GB9314884D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
| IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5679683A (en) * | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| TW414798B (en) | 1994-09-07 | 2000-12-11 | Thomae Gmbh Dr K | Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| TW321649B (en:Method) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| PT790997E (pt) | 1994-11-14 | 2000-06-30 | Warner Lambert Co | 6-aril pirido¬2,3-d|pirimidinas e naftiridinas para inibir a proliferacao celular mediada pela quinase da tirosina proteica |
| GB9424233D0 (en) | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| EP0802914B1 (en) | 1995-11-14 | 2001-06-06 | PHARMACIA & UPJOHN S.p.A. | Aryl- and heteroaryl- purine and pyridopyrimidine derivatives |
| ES2186908T3 (es) | 1996-07-13 | 2003-05-16 | Glaxo Group Ltd | Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas. |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| US6207669B1 (en) | 1996-07-13 | 2001-03-27 | Glaxo Wellcome Inc. | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
| IL129825A0 (en) * | 1996-11-27 | 2000-02-29 | Pfizer | Fused bicyclic pyrimidine derivatives |
-
1997
- 1997-07-08 HR HR9625492.5A patent/HRP970371A2/hr not_active Application Discontinuation
- 1997-07-11 PE PE1997000611A patent/PE91198A1/es not_active Application Discontinuation
- 1997-07-11 AP APAP/P/1999/001434A patent/AP9901434A0/en unknown
- 1997-07-11 EP EP97930518A patent/EP0912570B1/en not_active Expired - Lifetime
- 1997-07-11 PL PL97331221A patent/PL331221A1/xx unknown
- 1997-07-11 AR ARP970103102A patent/AR007856A1/es unknown
- 1997-07-11 BR BR9710359A patent/BR9710359A/pt not_active Application Discontinuation
- 1997-07-11 CA CA002260061A patent/CA2260061A1/en not_active Abandoned
- 1997-07-11 WO PCT/EP1997/003674 patent/WO1998002438A1/en not_active Ceased
- 1997-07-11 US US09/214,270 patent/US6174889B1/en not_active Expired - Fee Related
- 1997-07-11 ID IDP972412A patent/ID19403A/id unknown
- 1997-07-11 AT AT97930518T patent/ATE249458T1/de not_active IP Right Cessation
- 1997-07-11 JP JP10505598A patent/JP2000514445A/ja not_active Ceased
- 1997-07-11 AU AU34439/97A patent/AU3443997A/en not_active Abandoned
- 1997-07-11 EP EP02080417A patent/EP1304110A3/en not_active Withdrawn
- 1997-07-11 IL IL12779697A patent/IL127796A0/xx unknown
- 1997-07-11 CN CN97197876A patent/CN1230187A/zh active Pending
- 1997-07-11 ES ES97930518T patent/ES2206729T3/es not_active Expired - Lifetime
- 1997-07-11 EA EA199900022A patent/EA199900022A1/ru unknown
- 1997-07-11 CZ CZ9989A patent/CZ8999A3/cs unknown
- 1997-07-11 YU YU1099A patent/YU1099A/sr unknown
- 1997-07-11 TR TR1999/00049T patent/TR199900049T2/xx unknown
- 1997-07-11 DE DE69724789T patent/DE69724789T2/de not_active Expired - Fee Related
-
1998
- 1998-12-31 IS IS4939A patent/IS4939A/is unknown
-
1999
- 1999-01-12 NO NO990124A patent/NO990124L/no not_active Application Discontinuation
- 1999-01-13 KR KR1019997000298A patent/KR20000023812A/ko not_active Withdrawn
-
2000
- 2000-06-30 US US09/608,971 patent/US6723726B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998002438A1 (en) | 1998-01-22 |
| EP1304110A3 (en) | 2003-12-17 |
| PL331221A1 (en) | 1999-07-05 |
| IL127796A0 (en) | 1999-10-28 |
| CN1230187A (zh) | 1999-09-29 |
| DE69724789D1 (de) | 2003-10-16 |
| EP0912570A1 (en) | 1999-05-06 |
| DE69724789T2 (de) | 2004-07-01 |
| PE91198A1 (es) | 1999-01-15 |
| BR9710359A (pt) | 1999-08-17 |
| HRP970371A2 (en) | 1998-08-31 |
| US6174889B1 (en) | 2001-01-16 |
| YU1099A (en) | 1999-11-22 |
| US6723726B1 (en) | 2004-04-20 |
| CZ8999A3 (cs) | 1999-06-16 |
| NO990124D0 (no) | 1999-01-12 |
| JP2000514445A (ja) | 2000-10-31 |
| EP1304110A2 (en) | 2003-04-23 |
| AU3443997A (en) | 1998-02-09 |
| IS4939A (is) | 1998-12-31 |
| AP9901434A0 (en) | 1999-03-31 |
| EA199900022A1 (ru) | 1999-08-26 |
| NO990124L (no) | 1999-03-11 |
| ID19403A (id) | 1998-07-09 |
| AR007856A1 (es) | 1999-11-24 |
| ATE249458T1 (de) | 2003-09-15 |
| KR20000023812A (ko) | 2000-04-25 |
| EP0912570B1 (en) | 2003-09-10 |
| CA2260061A1 (en) | 1998-01-22 |
| TR199900049T2 (xx) | 1999-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2206729T3 (es) | Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosina quinasa. | |
| EP0912572B1 (en) | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | |
| EP0912559B1 (en) | Fused heterocyclic compounds as protein tyrosine kinase inhibitors | |
| US10280166B2 (en) | 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof | |
| ES2295035T3 (es) | Anilinoquinazolinas como inhibidores de proteina tirosina quinasa. | |
| US10202377B2 (en) | 3-(1H-benzo[D]imidazol-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof | |
| ES2262087T3 (es) | Compuestos heteroaromiticos biciclicos como inhibidores de proteina tirosina cinasa. | |
| US10350199B2 (en) | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof | |
| ES2427166T3 (es) | Compuesto heterocíclico tricíclico novedoso | |
| WO1999035132A1 (en) | Heterocyclic compounds | |
| WO2016040182A1 (en) | 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof | |
| TW200914443A (en) | Process for preparing substituted quinazolinyl furanaldehyde | |
| WO1997013771A1 (en) | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | |
| US20180221350A1 (en) | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof | |
| WO2017023986A1 (en) | 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof | |
| EP0843671A1 (en) | Heterocyclic compounds and pharmaceutical compositions containing them | |
| BRPI0608160A2 (pt) | anticorpo isolado, célula hospedeira, método de inibir o crescimento de células psma+, e, uso de um anticorpo anti-psma defucosilado | |
| KR20080108129A (ko) | 크로메인 유도체 |